Signaling pathways in renal cell carcinoma

Cancer Biology and Therapy

Volumn 10, Issue 7, 2010, Pages 658-664

  Banumathy, Gowrishankar ^a   Cairns, Paul ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Epigenetics; Genetics; Kinases; mTOR; RCC; Signaling pathways; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BETA CATENIN; BEVACIZUMAB; DEFEROLIMUS; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VON HIPPEL LINDAU PROTEIN; WNT PROTEIN;

ANGIOGENESIS; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL SURVIVAL; DRUG ACTIVITY; DRUG MEGADOSE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957549861     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.7.13247     Document Type: Review

References (104)

1. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22:454-63. (Pubitemid 41079774)
2. Grossman E, Messerli FH. Diuretics and renal cell carcinoma - What is the risk/benefit ratio? Kidney Int 1999; 56:1603-4.
3. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004; 4:381-93.
4. Zbar B, Klausner R, Linehan WM. Studying cancer families to identify kidney cancer genes. Annu Rev Med 2003; 54:217-33. (Pubitemid 37386393)
5. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, et al. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer 2009; 8:31.
6. Ratcliffe PJ. New insights into an enigmatic tumour suppressor. Nat Cell Biol 2003; 5:7-8. (Pubitemid 36054319)
7. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673-82.
8. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18:2343-50. (Pubitemid 29192711)
9. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-90.
10. Valladares Ayerbes M, Aparicio Gallego G, Diaz Prado S, Jimenez Fonseca P, Garcia Campelo R, Anton Aparicio LM. Origin of renal cell carcinomas. Clin Transl Oncol 2008; 10:697-712.
11. Kiuru M, Lehtonen R, Arola J, Salovaara R, Jarvinen H, Aittomaki K, et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 2002; 62:4554-7.
12. Gad S, Lefevre SH, Khoo SK, Giraud S, Vieillefond A, Vasiliu V, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 2007; 96:336-40.
13. Polascik TJ, Cairns P, Epstein JI, Fuzesi L, Ro JY, Marshall FF, et al. Distal nephron renal tumors: microsatellite allelotype. Cancer Res 1996; 56:1892-5.
14. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7:277-85.
15. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-30.
16. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33.
17. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26:225-39.
18. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003; 9:4641-52.
19. Clifford SC, Walsh S, Hewson K, Green EK, Brinke A, Green PM, et al. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renalcell carcinoma development. Genes Chromosomes Cancer 1999; 26:20-8.
20. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625-34.
21. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
22. Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation and oxygen sensing. Biochem Biophys Res Commun 2005; 338:627-38.
23. Kaelin WG. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol 2005; 70:159-66.
24. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587-95.
25. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435-46.
26. Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death and radiation responses. Proc Natl Acad Sci USA 2009; 106:14391-6.
27. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64:993-8.
28. Sun Q, Zhou H, Binmadi NO, Basile JR. Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem 2009; 284:32066-74.
29. Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest 2008; 88:962-72.
30. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis and Therapy. Eur Urol 2010; 58:75-83.
31. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, et al. Identification of a microRNA panel for clearcell kidney cancer. Urology 2009; 75:835-41.
32. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009.
33. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35:856-67.
34. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278:687-9. (Pubitemid 27464966)
35. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282:1318-21. (Pubitemid 28524494)
36. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21:893-901.
37. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511.
38. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84.
39. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45.
40. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 2006; 36:283-93.
41. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39. (Pubitemid 28458022)
42. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999; 96:6199-204.
43. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005; 24:7391-3.
44. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005; 16:928-33. (Pubitemid 40903919)
45. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16:3215-8.
46. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31:99-109.
47. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5:997-1014.
48. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469-80.
49. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69:4674-81.
50. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007; 67:3171-6. (Pubitemid 46724854)
51. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126:955-68. (Pubitemid 44310775)
52. Kim YS, Kang YK, Kim JB, Han SA, Kim KI, Paik SR. beta-catenin expression and mutational analysis in renal cell carcinomas. Pathol Int 2000; 50:725-30.
53. Sansom OJ, Griffiths DF, Reed KR, Winton DJ, Clarke AR. Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene 2005; 24:8205-10.
54. Qian CN, Knol J, Igarashi P, Lin F, Zylstra U, Teh BT, et al. Cystic renal neoplasia following conditional inactivation of apc in mouse renal tubular epithelium. J Biol Chem 2005; 280:3938-45. (Pubitemid 40223863)
55. Saadi-Kheddouci S, Berrebi D, Romagnolo B, Cluzeaud F, Peuchmaur M, Kahn A, et al. Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene 2001; 20:5972-81. (Pubitemid 32955039)
56. Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003; 63:8695-9.
57. Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci USA 2006; 103:14531-6.
58. Kojima T, Shimazui T, Hinotsu S, Joraku A, Oikawa T, Kawai K, et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 2009; 28:297-305.
59. Awakura Y, Nakamura E, Ito N, Kamoto T, Ogawa O. Methylation-associated silencing of SFRP1 in renal cell carcinoma. Oncol Rep 2008; 20:1257-63.
60. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Kawakami K, et al. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 2009; 15:5678-87.
61. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Yamamura S, Kawakami K, et al. Wnt antagonist gene polymorphisms and renal cancer. Cancer 2009; 115:4488-503.
62. Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, Majid S, et al. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 2009; 69:8603-10.
63. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 2006; 12:383-91.
64. Linehan WM, Rubin JS, Bottaro DP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol 2009; 41:753-6.
65. Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, et al. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 2008; 10:1208-16.
66. Berndt JD, Moon RT, Major MB. Beta-catenin gets jaded and von Hippel-Lindau is to blame. Trends Biochem Sci 2009; 34:101-4.
67. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008; 10:295-305.
68. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005; 5:699-712.
69. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:131-42.
70. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004; 10:3972-9. (Pubitemid 38812470)
71. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant downregulation of miR-141 and miR-200c. J Pathol 2008; 216:418-27.
72. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601. (Pubitemid 351627379)
73. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9:582-9. (Pubitemid 351772923)
74. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22:894-907.
75. Weber K, Doucet M, Kominsky S. Renal cell carcinoma bone metastasis - elucidating the molecular targets. Cancer Metastasis Rev 2007; 26:691-704. (Pubitemid 350115120)
76. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGFbeta. Future Oncol 2009; 5:1145-68.
77. Peruzzi B, Jean-Baptiste L, Bottaro DP. The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ, Eds. Renal Cell Carcinoma: Humana Press 2009; 327.
78. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73.
79. Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met protooncogene. J Urol 2004; 172:1256-61.
80. Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, et al. Duplication and overexpression of the mutant allele of the MET protooncogene in multiple hereditary papillary renal cell tumours. Oncogene 1998; 17:733-9. (Pubitemid 28412494)
81. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009; 9:785-93.
82. Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 2008; 14:5941-6.
83. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15:2207-14.
84. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002; 62:2064-71.
85. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463:360-3.
86. Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 1995; 55:224-7.
87. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9:407-15. (Pubitemid 36460074)
88. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120:3163-72.
89. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22. (Pubitemid 37328883)
90. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39:347-51.
91. Di Lorenzo G, Autorino R, Sternberg CN. Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. Eur Urol 2009; 56:959-71.
92. Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer - when TKIs are not enough. Nat Rev Clin Oncol 2009; 6:478-87.
93. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35. (Pubitemid 46630490)
94. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-37.
95. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-8.
96. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-81. (Pubitemid 46849157)
97. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66:5549-54. (Pubitemid 43927103)
98. Houghton PJ. Everolimus. Clin Cancer Res 2010; 16:1368-72.
99. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8:579-91.
100. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010; 70:1053-62.
101. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 2009; 104:1585-9.
102. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13:3109-14.
103. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278-87.
104. Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 2009; 7:659-65.